IP Library › Granted Patent US 9,512,112
Granted Patent B2
US 9,512,112 · App. 14/328,959 · Granted Dec 6, 2016

Substituted pyridines as P2X

Inventors: Li Chen (Shanghai, CN); Michael Patrick Dillon (San Francisco, CA); Lichun Feng (Shanghai, CN); Minmin Yang (Nanjing, CN)
Assignee: Roche Palo Alto LLC
C07D413/12C07D207/27C07D233/32C07D263/20C07D403/12C07D407/14C07D413/10C07D413/14C07D473/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,512,112
App. No.
14/328,959
Granted
Dec 6, 2016
Kind
B2
Abstract

Compounds of the formula I: or a pharmaceutically acceptable salt thereof, wherein, X, Y, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and R 7 are as defined herein. Also disclosed are methods of using the compounds for treating diseases associated with P2X 3 and/or a P2X 2/3 receptor antagonists and methods of making the compounds.

Claims (25)

1. A method for modulating P2X 3 and P2X 2/3 receptor activity in a subject, comprising administering to a subject in need thereof an effective amount of a compound of formula I, or a pharmaceutically acceptable salt thereof,

wherein:

R 1 is C 1-6 alkyl or halo;

R 2 is C 3-6 cycloalkyl, C 1-6 alkoxy-C 1-6 alkyl, hydroxy-C 1-6 alkyl or heteroaryl-C 1-6 alkyl, wherein heteroaryl is pyrazinyl, pyridazinyl or pyrimidinyl, each optionally substituted once with methyl;

R 3 is hydrogen, halo, C 1-6 alkyl or C 1-6 alkoxy-carbonyl;

R 4 is hydrogen, halo or C 1-6 alkyl; or

R 3 and R 4 , together with the atoms to which they are attached, may form a fused 6-membered aromatic ring that optionally includes one or two nitrogens and which is optionally substituted with 0, 1 or 2 R 8 substituents, wherein R 8 is C 1-6 alkyl, C 1-6 alkoxy, C 1-6 alkyl-sulfonyl, halo-C 1-6 alkyl or halo; or

R 3 and R 4 , together with the atom to which they are attached, may form C 3-6 cycloalkyl;

R 5 , R 6 and R 7 are each independently hydrogen or fluoro;

X is —N—; and

Y is —O— or —NR c —, wherein R c is hydrogen or C 1-6 alkyl.

2. The method of claim 1 , wherein:

R 5 , R 6 and R 7 are independently hydrogen;

R 1 is methyl; and

R 2 is cyclopropyl, 2-methoxy-1-methylethyl, 2-hydroxy-1-methylethyl, 5-methyl-pyrazin-2-ylmethyl, 1-pyrazin-2-ylethyl, pyrimidin-5-ylmethyl, 6-methyl-pyridazin-3-ylmethyl, pyridazin-3-ylmethyl, 5-methyl-pyrimidin-2-ylmethyl or 2-methyl-pyrimidin-5-ylmethyl.

3. The method of claim 2 , wherein:

R 2 is 2-hydroxy-1-methylethyl, 5-methyl-pyrazin-2-ylmethyl or 1-pyrazin-2-ylethyl.

4. A method for modulating P2X 3 and P2X 213 receptor activity in a subject, comprising administering to a subject in need thereof an effective amount of a compound of formula III, or a pharmaceutically acceptable salt thereof,

wherein:

R 1 is C 1-6 alkyl or halo;

R 2 is C 3-6 cycloalkyl, C 1-6 alkoxy-C 1-6 alkyl, hydroxy-C 1-6 alkyl or heteroaryl-C 1-6 alkyl, wherein heteroaryl is pyrazinyl, pyridazinyl or pyrimidinyl, each optionally substituted once with methyl;

X is —N—;

Y is —O—, —CH 2 — or —NH—;

R 8 is C 1-6 alkyl, C 1-6 alkoxy, C 1-6 alkyl-sulfonyl, halo-C 1-6 alkyl or halo; and

n is 0, 1 or 2.

Assignments (1)
SECURITY INTEREST Recorded Sep 2, 2026
From: WESTERN ALLIANCE BANK
To: TAMR, INC.
Reel/Frame 075881/0661 →
Continuity (4)
Continuation 13314529 · Dec 8, 2011
Division 12820660 · Jun 22, 2010
Provisional Application 61219022 · Jun 22, 2009
Related Publication 20140323499A1 · Oct 30, 2014